AnaSCI - Fitness Evolved

Buy Needles and Syringes with NO PRESCRIPTION   Synthetek Muscle Building And Fat Loss Products   Cheap Pure Supplements

©ALL CONTENT OF THIS WEBSITE IS COPYRIGHTED AND CANNOT BE REPRODUCED WITHOUT THE ADMINISTRATORS CONSENT 2003-2019

   
  Synthetek Syntherol  
   
   
   
Largest Selection of Bodybuilding Products   Largest Selection of Bodybuilding Products   Largest Selection of Bodybuilding Products


User CP FAQ Members List Calendar New Posts Quick Links Log Out

AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved


        
        
        
        
        

Automatic Translations (Powered by Yandex):
Albanian Belarusian Catalan Czech Danish Dutch English Estonian Finnish French German Greek Hungarian Italian Latvian Lithuanian Macedonian Norwegian Portuguese Russian Slovak Slovenian Spanish Swedish Turkish Ukrainian

Go Back   Anabolic Steroids Discussion and Bodybuilding Forum > Anabolic Science Section > Anabolic Science Forum

Reply
 
LinkBack Thread Tools Display Modes
newbie with knee problem...any suggestions?
Old
  (#1)
AnaSCI MEMBER
 
Offline
Posts: 2
Join Date: Mar 2005
newbie with knee problem...any suggestions? - 03-21-2005, 07:45 PM

I just joined as you can see, i have been recovering from some knee problems. A torn miniskus, torn mcl, and damaged cartilidge. Does anybody have any good suggestions on anything I could do to get some mobility back in it, or some alternative exercises that i could do that wouldnt be to risky to re-injure it? Thanks guys.
   
Reply With Quote
Old
  (#2)
Banned
 
dugie82's Avatar
 
Offline
Posts: 538
Join Date: May 2004
Location: Texas
03-21-2005, 09:25 PM

i hope you're not serious..

i went through rehab for my knee, believe me the last thing you need is gear. Your body has to heal itself, no amount of drugs is going to do that for you.

go to a PT if you havn't already.
   
Reply With Quote
Old
  (#3)
wolfyEVH
Guest
 
Posts: n/a
03-21-2005, 09:37 PM

I have personally never used this stuff, but lots of people swear by it.....not sure if its 100% for you, but it may be something to take into consideration.

TAKEN FROM CYPHON AT UF4L

************************************************** **************

FAST ACCESS TO THE JOINTS: Beneficial levels of Adequan are already at work in all major joints within two hours after intramuscular injection, with even greater uptake (up to 73% higher) in joint tissues that are inflamed or diseased. LONG-TERM EFFECTS: Adequan relieves the pain and disability of joint damage, and the relief has been shown to last up to 6 months or longer. BREAKS THE DESTRUCTIVE CYCLE: Adequan binds to damaged cartilage and boosts cartilage metabolism, facilitating repair processes. At the same time, it blocks the action of destructive enzymes that promote joint inflammation, break down the synovial fluid, and attack the cartilage. RENEWS THE JOINT FLUID: Adequan stimulates the synovial membrane to manufacture new synovial fluid to replace the thin, degraded fluid of joint disease. By doing so, Adequan helps lubricate, nourish, and clean the cartilage.

Administration: An initial 8-dose series is recommended: 2 mg/lb intramuscularly twice a week for four weeks. Adequan is packaged in 5 mL (100 mg/mL or 500mg/ml) multidose vials .




Adequan Information
Description: The active ingredient in Adequan® is polysulfated glycosaminoglycan (PSGAG). Polysulfated glycosaminoglycan is a semi-synthetic glycosaminoglycan prepared by extracting glycosaminoglycans (GAGs) from bovine tracheal cartilage. GAGs are polysaccharides composed of repeating disaccharide units. The GAG present in PSGAG is principally chondroitin sulfate containing 3 to 4 sulfate esters per disaccharide unit. The molecular weight for PSGAG used in the manufacture of Adequan® is 3,000 to 15,000 daltons. Each mL of Adequan® contains 100 mg or 500mg of PSGAG, 0.9% v/v benzyl alcohol as a preservative, and water for injection q.s. to 1 mL. Sodium hydroxide and/or hydrochloric acid added when necessary to adjust pH.

Pharmacology: The specific mechanism of action of Adequan® in joints is not known. PSGAG is characterized as a "disease modifying osteoarthritis drug." Experiments conducted in vitro have shown PSGAG to inhibit certain catabolic enzymes which have increased activity in inflamed joints, and to enhance the activity of some anabolic enzymes. For example, PSGAG has been shown to significantly inhibit serine proteinases. Serine proteinases have been demonstrated to play a role in the Interleukin-1 mediated degradation of cartilage proteoglycans and collagen. PSGAG is reported to be an inhibitor of Prostaglandin E2 (PGE2) synthesis. PGE2 has been shown to increase the loss of proteoglycan from cartilage. PSGAG has been reported to inhibit some catabolic enzymes such as elastase, stromelysin, metalloproteases, cathepsin B1, and hyaluronidases, which degrade collagen, proteoglycans, and hyaluronic acid in degenerative joint disease. Anabolic effects studied include ability to stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid in various cells and tissues in vitro. Cultured human and rabbit chondrocytes have shown increased synthesis of proteoglycan and hyaluronic acid in the presence of PSGAG. PSGAGs have shown a specific potentiating effect on hyaluronic acid synthesis by synovial membrane cells in vitro.

Absorption, distribution, metabolism, and excretion of PSGAG following intramuscular injection have been studied in several species, including rats, rabbits, humans, horses and dogs.

Studies in rabbits showed maximum blood concentrations of PSGAG following IM injection were reached between 20 to 40 minutes following injection, and that the drug was distributed to all tissues studied, including articular cartilage, synovial fluid, adrenals, thyroid, peritoneal fluid, lungs, eyes, spinal cord, kidneys, brain, liver, spleen, bone marrow, skin, and heart.

Following intramuscular injection of PSGAG in humans, the drug was found to be bound to serum proteins. PSGAG binds to both albumin and chi- and beta-globulins and the extent of the binding is suggested to be 30 to 40%. Therefore, the drug may be present in both bound and free form in the bloodstream. Because of its relatively low molecular weight, the synovial membrane is not a significant barrier to distribution of PSGAG from the bloodstream to the synovial fluid. Distribution from the synovial fluid to the cartilage takes place by diffusion. In the articular cartilage the drug is deposited into the cartilage matrix.

Serum and synovial fluid distribution curves of PSGAG have been studied in dogs and appear similar to those found in humans and rabbits.

In rabbits, metabolism of PSGAG is reported to take place in the liver, spleen, and bone marrow. Metabolism may also occur in the kidneys. PSGAG administered intramuscularly and not protein bound or bound to other tissues is excreted primarily via the kidneys, with a small proportion excreted in the feces.

Efficacy: Efficacy of Adequan® was demonstrated in two studies. A laboratory study using radiolabeled PSGAG established distribution of PSGAG into canine serum and synovial fluid following a single intramuscular injection of 2 mg/lb. A clinical field trial was conducted in dogs diagnosed with radiographically-confirmed traumatic and/or degenerative joint disease of 1 or 2 joints. Joints evaluated included hips, stifles, shoulders, hocks and elbows. Fifty-one dogs were ran***ly assigned to receive either Adequan® at 2 mg/lb of body weight or 0.9% saline. Both treatments were administered by intramuscular injection twice weekly for 4 weeks (8 injections total). Investigators administering treatment and evaluating the dogs were unaware of the treatment assignment. A total of 71 limbs in 51 dogs were evaluated. Of these, 35 limbs in 24 dogs were in the Adequan® treated group. Each lame limb was scored for lameness at a walk, lameness at a trot, pain, range of motion, and functional disability. The scores for the individual parameters were combined to determine a total orthopedic score. At the end of the treatment period, dogs treated with Adequan® showed a statistically significant improvement in range of motion and total orthopedic score over placebo treated control dogs.

Indications and Usage: Adequan® is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of synovial joints.

Prices range from $50 -$200 depending on source and dose.
   
Reply With Quote
Old
  (#4)
AnaSCI MEMBER
 
Offline
Posts: 2
Join Date: Mar 2005
03-21-2005, 10:04 PM

much thanks br!o, i will definately check in to that. thanks again
   
Reply With Quote
Old
  (#5)
Steroid Nazi
 
DragonRider's Avatar
 
Offline
Posts: 3,717
Join Date: Jan 2004
Location: The shadows of your mind
03-21-2005, 10:39 PM

Welcome to the board.


Disclaimer: Anasci.org and DragonRider do not promote the use of anabolic steroids without a doctor's prescription. The information we share is for entertainment purposes only.

"NO STEROIDS FOR YOU!"
   
Reply With Quote
Old
  (#6)
AnaSCI FREAK
 
Gettinhuge_pump's Avatar
 
Offline
Posts: 379
Join Date: Dec 2004
Location: In the hills of the southeastern U.S.
03-23-2005, 05:19 PM

Greene huh? Not a Tusculum College football player are ya? lol
   
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are On
Pingbacks are On
Refbacks are On



All times are GMT -4. The time now is 03:14 PM.



Content Relevant URLs by vBSEO 3.6.0
Copyright © 2003-2019 AnaSCI.org. All rights reserved.